ClinicalTrials.gov ID NCT06710197
Sponsor University Health Network, Toronto
Information provided by University Health Network, Toronto (Responsible Party)
Last Update Posted 2025-03-11
Study Overview
Brief Summary
This study will examine changes in the tumor microenvironment (TME) induced by 14 days of pre-operative IL-1-inhibiting therapy among patients with early breast cancer (including TNBC and ER-low positive). Key immune biomarkers (TILs, TAMs, NK cells, IL1[beta] and inflammasome component expression) will be evaluated at baseline and following 14 days of IL-1 antagonist therapy (Anakinra) using paired tissue specimens.